CNX-774 is a potent Btk inhibitor (IC50 < 1 nM). Recently Bruton's tyrosine kinase (BTK) , a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.
BTK inhibitor Related Prodcuts:
Ibrutinib; Spebrutinib; Remibrutinib; Evobrutinib; Acalabrutinib; Olmutinib; ONO-4059 analog; RN486; CGI-1746; Zanubrutinib